Samsara BioCapital’s Aimmune Therapeutics AIMT Stock Holding History

Samsara BioCapital’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-58,142	Closed	-$2M	–	46
2020 Q3	$2M	Sell	58,142 -174,429	-75%	-$3.71M	0.56%	28
2020 Q2	$3.89M	Hold	232,571	–	–	1.25%	20
2020 Q1	$3.35M	Buy	+232,571	New	+$5.94M	1.93%	15

Samsara BioCapital's AIMT Position: Q4 2020 in Review

Samsara BioCapital sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 58,142 shares — an estimated $2M sold.

Samsara BioCapital first reported a position in AIMT in Q1 2020 and held it in 3 quarters. The position peaked at $3.89M in Q2 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Samsara BioCapital reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Samsara BioCapital sold 58,142 Aimmune Therapeutics shares in Q4 2020, an estimated $2M.
Samsara BioCapital first reported a position in Aimmune Therapeutics in Q1 2020 and held it in 3 quarters.
Samsara BioCapital's Aimmune Therapeutics position peaked at $3.89M in Q2 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Samsara BioCapital's 13F filing for Q4 2020, filed 17 Feb 2021.